SCHEMBL4520699

SCHEMBL4520699

CCc1ccc(-c2ccc(C(N)=O)cc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 1/20 0.58
ALDH1A1 P00352 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.55
PLK1 P53350 1/20 0.52
PLA2G10 O15496 1/20 0.52
PLA2G2A P14555 1/20 0.52
RXRA P19793 1/20 0.52
RXRB P28702 1/20 0.52
NQO2 P16083 1/20 0.51
CHEK2 O96017 4/20 0.50
PARP10 Q53GL7 3/20 0.50
CA12 O43570 1/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
CA9 Q16790 1/20 0.50
CA14 Q9ULX7 1/20 0.50
BCL2 P10415 1/20 0.47
MKNK1 Q9BUB5 3/20 0.47
MKNK2 Q9HBH9 3/20 0.47
MMP2 P08253 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10243616 1.00 CYP17A1 (0.58) CYP17A1ALDH1A1SMN1; SMN2PLK1PLA2G10
SCHEMBL178439 0.94 ALDH1A1 (0.64) CYP17A1ALDH1A1SMN1; SMN2PLK1PLA2G10
Benzamide SCHEMBL27520826 0.83 L3MBTL1 (0.67) ALDH1A1SMN1; SMN2PLK1PLA2G10PLA2G2A
SCHEMBL9420265 0.83 ALDH1A1 (0.61) ALDH1A1SMN1; SMN2PLK1RXRARXRB
SCHEMBL21628385 0.82 PARP10 (0.70) ALDH1A1SMN1; SMN2RXRARXRBCHEK2
SCHEMBL10243641 0.82 BCL2 (0.55) BCL2
SCHEMBL10243328 0.82 BCL2 (0.55) BCL2
SCHEMBL1002578 0.82 CA2 (0.67) CYP17A1ALDH1A1PARP10CA12CA1
Trifluoroacetic Acid SCHEMBL7850274 0.81 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2PLK1PLA2G10PLA2G2A
SCHEMBL15750344 0.81 RARB (0.72) CYP17A1ALDH1A1PLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250354151-A1 INHIBITORY AGENT FOR MYOCARDIAL CELL DEATH, AND PROPHYLACTIC OR THERAPEUTIC AGENT FOR MYOCARDIAL DISORDERS OR HEART FAILURE KYOTO PREFECTURAL PUBLIC UNIV CORP (JP) 2025-11-20 US disclosed
WO-2021119249-A1 CYCLOPHILIN D INHIBITORS AND USES THEREOF THE BROAD INSTITUTE, INC. (US) 2021-06-17 WO disclosed
US-10196373-B2 Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of STAT protein THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2019-02-05 US disclosed
US-20160158207-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2016-06-09 US disclosed
EP-2295402-B1 Antibacterial agents UNIV WASHINGTON (US) 2015-08-12 EP disclosed
US-20150038708-A1 SUBSTITUTED 2-HYDROXY-4-(2-(PHENYLSULFONAMIDO)ACETAMIDO)BENZOIC ACID ANALOGS AS INHIBITORS OF STAT PROTEIN NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-02-05 US disclosed
US-8846707-B2 Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of stat protein UNIVERISTY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) 2014-09-30 US disclosed
WO-2012018868-A1 SUBSTITUTED 2-HYDROXY-4-(2-(PHENYLSULFONAMIDO)ACETAMIDO)BENZOIC ACID ANALOGS AS INHIBITORS OF STAT PROTEINS UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) 2012-02-09 WO disclosed
US-8084615-B2 Antibacterial agents UNIVERSITY OF WASHINGTON (US) 2011-12-27 US disclosed
US-7579479-B2 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method BRISTOL-MYERS SQUIBB COMPANY (US) 2009-08-25 US disclosed
US-20090163496-A1 ANTIBACTERIAL AGENTS UNIVERSITY OF WASHINGTON (US) 2009-06-25 US disclosed
US-20070208166-A1 Tao Kinase Modulators And Method Of Use EXELIXIS, INC. (US) 2007-09-06 US disclosed
US-20070015797-A1 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method CHENG PETER T 2007-01-18 US disclosed
WO-2005014533-A2 ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE TRANSTECH PHARMA, INC. (US) 2005-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250354151-A1 INHIBITORY AGENT FOR MYOCARDIAL CELL DEATH, AND PROPHYLACTIC OR THERAPEUTIC AGENT FOR MYOCARDIAL DISORDERS OR HEART FAILURE TNNI3, TNNC1, TNNT2 CYP17A1 4097/4885ALDH1A1 3769/4885SMN1; SMN2 3254/4885
US-20160158207-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF EP300, HDAC1, HDAC10 CYP17A1 2305/4885ALDH1A1 1727/4885SMN1; SMN2 1776/4885
US-20150038708-A1 SUBSTITUTED 2-HYDROXY-4-(2-(PHENYLSULFONAMIDO)ACETAMIDO)BENZOIC ACID ANALOGS AS INHIBITORS OF STAT PROTEIN STAT3, STAT1, STAT4 CYP17A1 3331/4885ALDH1A1 4285/4885SMN1; SMN2 3165/4885
US-20090163496-A1 ANTIBACTERIAL AGENTS MRPL21, SI, PGLS CYP17A1 1104/4885ALDH1A1 782/4885SMN1; SMN2 2296/4885
US-10196373-B2 Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of STAT protein STAT3, STAT1, STAT4 CYP17A1 3331/4885ALDH1A1 4285/4885SMN1; SMN2 3165/4885
US-20070208166-A1 Tao Kinase Modulators And Method Of Use TAOK1, TAOK3, MAP3K6 CYP17A1 4360/4885ALDH1A1 4424/4885SMN1; SMN2 4552/4885
US-20070015797-A1 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method GPR119, LIPC, ACACA CYP17A1 1178/4885ALDH1A1 1055/4885SMN1; SMN2 4228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.